Suggested remit: To appraise the clinical and cost effectiveness of pembrolizumab within its marketing authorisation for adjuvant treatment of renal cell carcinoma after nephrectomy.
|
Status
|
In progress
|
|
Decision
|
Selected
|
| Process |
STA 2018
|
| ID number |
3810
|
Provisional Schedule
| Expected publication |
20 July 2022 |
Project Team
| Project lead |
Shonagh D'Sylva |
Email enquiries
| External Assessment Group |
BMJ Technology Assessment Group (BMJ-TAG), BMJ |
Stakeholders
| Companies sponsors |
MSD (pembrolizumab) |
| Others |
Department of Health and Social Care |
| |
NHS England |
| |
Welsh Government |
| Patient carer groups |
Kidney Cancer Support Network |
| |
Kidney Cancer UK |
| Professional groups |
Association of Cancer Physicians |
| |
British Uro-oncology Group |
| |
Cancer Research UK |
| |
Royal College of Physicians |
| |
Royal College of Radiologists |
| Comparator companies |
None |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
British National Formulary |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare products Regulatory Agency |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
Institute of Cancer Research |
| |
National Institute for Health Research |
|
Date
|
Update
|
|
12 May 2022
|
Committee meeting: 1 |
|
02 September 2021
|
Invitation to participate |
|
31 August 2021
|
We recently contacted all stakeholders for the appraisal of pembrolizumab for adjuvant treatment of renal cell carcinoma regarding a delay to this topic for operational reasons.
Pembrolizumab for adjuvant treatment of renal cell carcinoma has now been rescheduled into the work programme. The appraisal is due to start early September 2021 and will be discussed at committee in mid-May 2022.
The new timelines are subject to the work programme capacity and we will continue to review our plans in collaboration with the company and update our stakeholders accordingly. |
|
17 June 2021
|
Timelines for this appraisal are to be confirmed. Further information regarding the scheduling of this appraisal will be available in due course. |
|
16 November 2020 - 14 December 2020
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
|
02 August 2019
|
In progress. DHSC referral received 02/08/2019 |
For further information on our processes and methods, please see our CHTE processes and methods manual